Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR) presented interim data at the 5th Annual Symposium on Hidradenitis Suppurativa Advances, revealing insights from a non-interventional trial on IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study highlighted the effectiveness of KT-474, an IRAK4-targeted protein degrader, in lowering IRAK4 levels in blood mononuclear cells. With a Phase 1 trial expected to start in 2021, these findings support the potential of IRAK4 degraders in treating HS and other inflammatory diseases, addressing a critical unmet medical need.
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointment of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Both bring extensive biopharmaceutical experience, enhancing Kymera's leadership during a pivotal growth phase. Dr. Esposito has been instrumental in raising over $400M for Replimune's oncolytic therapies, while Albers led Blueprint Medicines through a successful IPO. Their expertise is expected to advance Kymera's strategic direction and innovative treatment options for cancer and autoimmune diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced the closing of its upsized initial public offering, selling 9,987,520 common shares at $20.00 per share, yielding approximately $199.8 million in gross proceeds. This includes 1,302,720 shares purchased by underwriters' option. Additionally, Kymera completed a private placement of 676,354 shares to Vertex Pharmaceuticals, raising $13.5 million. Registration statements for these offerings were effective as of August 20, 2020. All shares were sold by Kymera, aimed at advancing targeted protein degradation therapeutics.